CN1780838A - 新型二氮杂双环壬烯衍生物 - Google Patents

新型二氮杂双环壬烯衍生物 Download PDF

Info

Publication number
CN1780838A
CN1780838A CNA2004800116500A CN200480011650A CN1780838A CN 1780838 A CN1780838 A CN 1780838A CN A2004800116500 A CNA2004800116500 A CN A2004800116500A CN 200480011650 A CN200480011650 A CN 200480011650A CN 1780838 A CN1780838 A CN 1780838A
Authority
CN
China
Prior art keywords
mixture
alkyl group
low alkyl
compound
racemic mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800116500A
Other languages
English (en)
Chinese (zh)
Inventor
奥利维尔·贝曾康
丹尼尔·比尔
瓦尔特·菲施利
尤博斯·雷门
西尔维娅·理查德-比洛斯泰恩
托马斯·韦勒
蒂埃里·西费朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN1780838A publication Critical patent/CN1780838A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004800116500A 2003-05-02 2004-04-26 新型二氮杂双环壬烯衍生物 Pending CN1780838A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP03/04622 2003-05-02
EP0304622 2003-05-02

Publications (1)

Publication Number Publication Date
CN1780838A true CN1780838A (zh) 2006-05-31

Family

ID=33395698

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800116500A Pending CN1780838A (zh) 2003-05-02 2004-04-26 新型二氮杂双环壬烯衍生物

Country Status (10)

Country Link
EP (1) EP1622564A2 (fr)
JP (1) JP2006525259A (fr)
KR (1) KR20060015573A (fr)
CN (1) CN1780838A (fr)
AU (1) AU2004233577A1 (fr)
BR (1) BRPI0409882A (fr)
CA (1) CA2521898A1 (fr)
MX (1) MXPA05011711A (fr)
RU (1) RU2005137571A (fr)
WO (1) WO2004096116A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004283821A1 (en) * 2003-10-13 2005-05-06 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives and their use as renin inhibitors
JP2007509099A (ja) * 2003-10-23 2007-04-12 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネンおよび新規極性側鎖を有するテトラヒドロピリジン誘導体
AU2004295092A1 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd. Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
WO2006021403A1 (fr) * 2004-08-25 2006-03-02 Actelion Pharmaceuticals Ltd Dérivés du bicyclononène
US8138340B2 (en) 2004-08-25 2012-03-20 Actelion Pharmaceuticals Ltd. Bicyclononene derivatives
WO2006058546A1 (fr) * 2004-12-01 2006-06-08 Actelion Pharmaceuticals Ltd Nouveaux dérivés de lactame en tant qu’inhibiteurs de la rénine
WO2006063610A1 (fr) * 2004-12-17 2006-06-22 Actelion Pharmaceuticals Ltd Dérivés de diazabicyclononène substitués par des groupements hétéroaryle
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
US7915259B2 (en) * 2005-01-28 2011-03-29 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives and use thereof
WO2006131884A2 (fr) * 2005-06-07 2006-12-14 Actelion Pharmaceuticals Ltd Nouveaux derives de thiazole
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2430139T3 (es) 2005-12-30 2013-11-19 Novartis Ag Compuestos de piperidina 3,5-sustituido como inhibidores de renina
US20100166839A1 (en) * 2006-03-16 2010-07-01 Nicox S.A Non peptidic renin inhibitors nitroderivatives
WO2008141462A1 (fr) 2007-05-24 2008-11-27 Merck Frosst Canada Ltd. Nouveaux inhibiteurs de rhénine
CN101687847B (zh) 2007-06-25 2013-11-06 诺华股份有限公司 用作肾素抑制剂的n5-(2-乙氧基乙基)-n3-(2-吡啶基)-3，5-哌啶二甲酰胺衍生物
US8334308B2 (en) 2007-08-20 2012-12-18 Merck Sharp & Dohme Corp. Renin inhibitors
SG192543A1 (en) 2008-05-05 2013-08-30 Merck Canada Inc 3, 4 - substituted piperidine derivatives as renin inhibitors
WO2013038936A1 (fr) * 2011-09-13 2013-03-21 タカラバイオ株式会社 Procédé d'arrêt d'une réaction peroxydasique, et agent d'arrêt pour ladite réaction

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509161A (en) * 1967-07-10 1970-04-28 Boehringer & Soehne Gmbh 3-phenyl-granatene-(2)-derivatives
WO1997009311A1 (fr) * 1995-09-07 1997-03-13 F. Hoffmann-La Roche Ag Nouvelles 4-(oxyalcoxyphenyl)-3-oxy-piperidines utiles pour traiter l'insuffisance cardiaque et renale
EP1501830B1 (fr) * 2002-04-29 2011-10-05 Actelion Pharmaceuticals Ltd. Derives de 7-aryl-3,9-diazabicyclo[3.3.1]non-6-ene et leur utilisation en tant qu'inhibiteurs de renine dans le traitement de l'hypertension, de maladies cardiovasculaires ou renales
EP1519920A1 (fr) * 2002-06-27 2005-04-06 Actelion Pharmaceuticals Ltd. Nouveaux derives de tetrahydropyridine en tant qu'inhibiteurs de renine

Also Published As

Publication number Publication date
CA2521898A1 (fr) 2004-11-11
KR20060015573A (ko) 2006-02-17
WO2004096116A2 (fr) 2004-11-11
EP1622564A2 (fr) 2006-02-08
AU2004233577A1 (en) 2004-11-11
JP2006525259A (ja) 2006-11-09
RU2005137571A (ru) 2006-05-10
BRPI0409882A (pt) 2006-05-23
WO2004096116A3 (fr) 2005-03-24
MXPA05011711A (es) 2006-01-23

Similar Documents

Publication Publication Date Title
CN1780838A (zh) 新型二氮杂双环壬烯衍生物
CN1281606C (zh) 含氮杂环化合物
EP3788045B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
CN1304365C (zh) 酰化的芳基环烷基胺和它们作为药物的用途
JP6505023B2 (ja) Ｃｎｓおよび他の障害を治療するための、ｐｄｅ４アイソザイムの阻害薬としてのアザベンゾイミダゾール化合物
JP7493586B2 (ja) Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法
CN1114604C (zh) 双环芳基甲酰胺及其治疗应用
JP2009514909A (ja) 肺高血圧を処置するためのジアリールウレア
CN1283183A (zh) 具有mmp和tnf抑制活性的异羟肟酸和羧酸衍生物
EP2990400B1 (fr) Composé acide dicarboxylique
JP3000564B2 (ja) Ｈｉｖプロテアーゼ阻害剤
CN115160339A (zh) 醛糖还原酶抑制剂及其使用方法
CN1780663A (zh) 作为肾素抑制剂的新型3－位具有杂原子的9－氮杂双环壬烯衍生物
CN104619327A (zh) 作为激酶抑制剂的氨基喹唑啉的前药
JP2017525765A (ja) 新規イミノニトリル誘導体
KR20120027268A (ko) 페녹시메틸 헤테로고리 화합물
CN1780833A (zh) 托品烷衍生物及其作为血管紧张肽转化酶抑制剂的应用
CN1890239A (zh) 二氮杂二环壬烯及带有新的侧链的四氢吡啶衍生物
AU2017223132B2 (en) 6,7-Dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
EP1828125B1 (fr) Derives d'arylpiperazine et leur utilisation comme ligands selectifs du recepteur d3 de la dopamine
CN1972912A (zh) 新型3,4－二取代的1,2,3,6－四氢吡啶衍生物
AU2016369653A1 (en) Alkynyl dihydroquinoline sulfonamide compounds
KR100784655B1 (ko) (+)-α-(2,3-디메톡시페닐)-1-[2-(4-플루오로페닐)에틸]-4-피페리딘메탄올 또는 이의 전구약물을 포함하는 치매 치료용 약제학적 조성물
CN1141940C (zh) 多环噻唑体系用于制备预防或治疗肥胖的药物的用途
CN1867568A (zh) 二氮杂二环壬烯衍生物及其作为血管紧张肽原酶抑制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication